ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.

Nicolas Kiavue, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Celine Callens, Florence Lerebours, Jean-Yves Pierga, Francois-Clement Bidard

Oncogene 2020 Jan

filter terms:

HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.

Citation

Nicolas Kiavue, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Celine Callens, Florence Lerebours, Jean-Yves Pierga, Francois-Clement Bidard. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2020 Jan;39(3):487-502